With the recent FDA approval of plasminogen, human-tvmh (Ryplazim; Kedrion BioPharma), there is now a treatment for plasminogen deficiency type 1, a rare disease in which the most common manifestation is ligneous conjunctivitis. Test your knowledge of the of this systemic disease here.
